肝脏脑病的预防:当前和未来的药物目标
Sudhir Maharshi1, Barjesh Chander Sharma2
1Department of Gastroenterology, SMS Medical College and Hospitals, Jaipur, India.
Hepatology international
|March 16, 2024
概括
肝脑病是一种由肝功能障碍引起的神经疾病,呈现出各种症状. 治疗包括乳糖,利法西明和较新的疗法,早期触发管理对于更好的结果至关重要.
科学领域:
- 神经学 神经学
- 肝病学 肝病学是一种肝病学.
- 胃肠病学 胃肠病学
背景情况:
- 肝发性脑病 (HE) 包括神经和精神症状,源于晚期肝功能障碍或移植系统的突变.
- 这意味着肝硬化患者的预后不佳,导致高死亡率,频繁住院和医疗费用增加.
- 主要预防预防预防最初的HE发作,而次要预防的目的是防止在患者有史以来的HE复发.
研究的目的:
- 审查目前对肝脏脑病的理解和管理策略.
- 突出既有和新兴治疗方法的疗效.
- 强调早期检测和HE患者的触发管理的重要性.
主要方法:
- 关于肝脏脑病治疗的文献综述.
- 对药理干预措施的分析,包括乳糖,利法西明等.
- 对手术和新型治疗方法的评估.
主要成果:
- 乳糖仍然是对最小的,明显的和复发性肝脏脑病变的首要治疗方法.
- 利法西明的疗效与乳糖相当,耐受性更好.
- 分支链氨基酸,L-ornithine L-aspartate和益生菌提供了额外的好处.
- 组合疗法 (Rifaximin + 乳糖) 对明显和复发性HE有效.
- 移植系统的分流栓塞和肝移植是选择患者的可行选择.
- 营养疗法和便微生物群移植等新兴疗法需要进一步的研究.
结论:
- 肝脏脑病的有效管理涉及早期触发因素的识别和量身定制的治疗策略.
- 像乳糖和利法西明这样的既定疗法是HE管理的基石.
- 新兴的治疗方法和支持性护理,包括药剂师参与和远程医疗,显示出希望.
- 需要进一步的研究来验证肝脏脑病的新疗法.
相关概念视频
01:22Alzheimer's Disease: Treatment
186
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
186
01:26Targets for Drug Action: Overview
6.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.2K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
123
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
123
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
396
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
396
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
292
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
292
01:14Antiepileptic Drugs: Glutamate Antagonists
342
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
342